Talaris Therapeutics (NASDAQ:TALS – Get Free Report) and Adverum Biotechnologies (NASDAQ:ADVM – Get Free Report) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, earnings, dividends, profitability, analyst recommendations, valuation and risk.
This is a summary of current recommendations for Talaris Therapeutics and Adverum Biotechnologies, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Talaris Therapeutics presently has a consensus target price of $7.50, suggesting a potential upside of 155.97%. Adverum Biotechnologies has a consensus target price of $3.00, suggesting a potential upside of 66.67%. Given Talaris Therapeutics’ higher possible upside, research analysts plainly believe Talaris Therapeutics is more favorable than Adverum Biotechnologies.
Institutional & Insider Ownership
Valuation and Earnings
This table compares Talaris Therapeutics and Adverum Biotechnologies’ gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Talaris Therapeutics||N/A||N/A||-$73.89 million||N/A||N/A|
|Adverum Biotechnologies||$7.50 million||24.24||-$154.54 million||($1.33)||-1.35|
Talaris Therapeutics has higher earnings, but lower revenue than Adverum Biotechnologies.
This table compares Talaris Therapeutics and Adverum Biotechnologies’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Volatility & Risk
Talaris Therapeutics has a beta of 2.27, indicating that its share price is 127% more volatile than the S&P 500. Comparatively, Adverum Biotechnologies has a beta of 0.86, indicating that its share price is 14% less volatile than the S&P 500.
Talaris Therapeutics beats Adverum Biotechnologies on 6 of the 10 factors compared between the two stocks.
About Talaris Therapeutics
Talaris Therapeutics, Inc. operates as a late-clinical stage cell therapy company in the United States. The company engages in developing a method of allogeneic hematopoietic stem cell transplantation to transform the standard of care in solid organ transplantation and severe autoimmune diseases, as well as severe blood, immune, and metabolic disorders. Its lead product candidate is FCR001, a novel allogeneic cell therapy that is in Phase II trial for living donor kidney transplant patients. The company is also developing FCR001 for the patients with a severe form of scleroderma. Talaris Therapeutics, Inc. was founded in 1988 and is headquartered in Wellesley, Massachusetts.
About Adverum Biotechnologies
Adverum Biotechnologies, Inc., a clinical-stage company, develops gene therapy product candidates to treat ocular and rare diseases. Its lead product candidate is ixoberogene soroparvovec (ADVM-022), a single intravitreal injection gene therapy candidate used for the treatment of patients with chronic retinal, including wet age-related macular degeneration and diabetic macular edema. The company is developing ADVM-062 (AAV.7m8-L-opsin), a novel gene therapy product candidate for the treatment of blue cone monochromacy via a single IVT injection. Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; GenSight Biologics; Lexeo Therapeutics; and Virovek, Inc. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California.
Receive News & Ratings for Talaris Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Talaris Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.